Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti‐tumor properties of PEDF with various efficacy and toxicity

Taxanes chemotherapies represent the major therapeutic alternative for symptomatic mCRPC. While docetaxel is the most commonly prescribed Taxane for mCRPC; cabazitaxel has been approved for patients unresponsive to docetaxel. Still mCRPC remains incurable and patients often experience severe side effects. Recently, the FIRSTANA trial first demonstrated the absence of superiority in overall survival between cabazitaxel and docetaxel in mCRPC patients. Inversely, different toxicity were reported suggesting that cabazitaxel may provide a first line treatment option for some patients urging for a deeper characterization of cabazitaxel mechanisms of action as well as a re‐evaluation of cabazitaxel conventional dose and schedule. In this study, our goal was therefore to evaluate the anti‐tumor efficacy of various cabazitaxel regimens delivered as monotherapy or in combination with PEDF, a known anti‐angiogenic and anti‐neoplastic agent.